Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

International T-Cell Lymphoma Project (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4558 · Cited by 2,108

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078

An inducible caspase 9 safety switch for T-cell therapy

Straathof, K. C., Pulè, M. A., Yotnda, P., Dotti, G., Vanin, E. F., Brenner, M. K., Heslop, H. E., Spencer, D. M., & Rooney, C. M. (2005) · Blood · doi:10.1182/blood-2004-11-4564 · Cited by 742

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

(1997) · PubMed · Cited by 697

Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas

Palomero, T., Couronné, L., Khiabanian, H., Kim, M.-Y., Ambesi-Impiombato, A., Perez-Garcia, A., Carpenter, Z., Abate, F., Allegretta, M., Haydu, J. E., et al. (2014) · Nature Genetics · doi:10.1038/ng.2873 · Cited by 619

A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells

Pulè, M. A., Straathof, K. C., Dotti, G., Heslop, H. E., Rooney, C. M., & Brenner, M. K. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.016 · Cited by 487

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project

Weisenburger, D. D., Savage, K. J., Harris, N. L., Gascoyne, R. D., Jaffe, E. S., MacLennan, K. A., Rüdiger, T., Pileri, S., Nakamura, S., Nathwani, B., et al. (2011) · Blood · doi:10.1182/blood-2010-09-310342 · Cited by 431

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy

Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., et al. (2014) · Blood · doi:10.1182/blood-2014-01-545020 · Cited by 397

Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing

Freeman, J. D., Warren, R. L., Webb, J. R., Nelson, B. H., & Holt, R. A. (2009) · Genome Research · doi:10.1101/gr.092924.109 · Cited by 385

A T-cell–directed chimeric antigen receptor for the selective treatment of T-cell malignancies

Mamonkin, M., Rouce, R. H., Tashiro, H., & Brenner, M. K. (2015) · Blood · doi:10.1182/blood-2015-02-629527 · Cited by 335

In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens

Dickinson, A. M., Wang, X.-N., Sviland, L., Vyth-Dreese, F. A., Jackson, G. H., Schumacher, T. N. M., Haanen, J. B. A. G., Mutis, T., & Goulmy, E. (2002) · Nature Medicine · doi:10.1038/nm0402-410 · Cited by 303

Stable, soluble T-cell receptor molecules for crystallization and therapeutics

Boulter, J. M., Glick, M., Todorov, P. T., Baston, E., Sami, M., Rizkallah, P., & Jakobsen, B. K. (2003) · Protein Engineering Design and Selection · doi:10.1093/protein/gzg087 · Cited by 276

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

Ramos, C. A., Savoldo, B., Torrano, V., Ballard, B., Zhang, H., Dakhova, O., Liu, E., Carrum, G., Kamble, R. T., Gee, A. P., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86000 · Cited by 276

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936

Brüggemann, M., White, H., Gaulard, P., Garcia-Sanz, R., Gameiro, P., Oeschger, S., Jasani, B., Ott, M., Delsol, G., Orfao, A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404481 · Cited by 240

Human RAG mutations: biochemistry and clinical implications

Notarangelo, L. D., Kim, M.-S., Walter, J. E., & Lee, Y. N. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.28 · Cited by 230

T Cell Receptor and Coreceptor CD8αα Bind Peptide-MHC Independently and with Distinct Kinetics

Wyer, J. R., Willcox, B. E., Gao, G. F., Gerth, U. C., Davis, S. J., Bell, J. I., van der Merwe, P. A., & Jakobsen, B. K. (1999) · Immunity · doi:10.1016/s1074-7613(00)80022-9 · Cited by 182

Variation in human T cell receptor Vβ and Jβ repertoire: analysis using anchor polymerase chain reaction

Rosenberg, W. M. C., Moss, P. A. H., & Bell, J. I. (1992) · European Journal of Immunology · doi:10.1002/eji.1830220237 · Cited by 162

Assembly, specific binding, and crystallization of a human TCR-αβ with an antigenic Tax peptide from human T lymphotropic virus type 1 and the class I MHC molecule HLA-A2

Garboczi, D. N., Utz, U., Ghosh, P., Seth, A., Kim, J., VanTienhoven, E. A., Biddison, W. E., & Wiley, D. C. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.12.5403 · Cited by 150

Immunophenotypic Analysis of Peripheral T-Cell Neoplasms

Jamal, S., Picker, L. J., Aquino, D. B., McKenna, R. W., Dawson, D. B., & Kroft, S. H. (2001) · American Journal of Clinical Pathology · doi:10.1309/qf6n-vaqw-n74h-4je2 · Cited by 125

Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells

Pinz, K. G., Liu, H.-L., Golightly, M. G., Jares, A., Lan, F., Zieve, G. W., Hagag, N. G., Schuster, M., Firor, A. E., Jiang, X., et al. (2015) · Leukemia · doi:10.1038/leu.2015.311 · Cited by 120

Sequence and evolution of the human T-cell antigen receptor beta-chain genes.

Tunnacliffe, A., Kefford, R. F., Milstein, C., Forster, A. M., & Rabbitts, T. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.15.5068 · Cited by 105

Generation of Monoclonal Antibodies Against a Human T Cell Receptor β Chain Expressed in Transgenic Mice

Viney, J. L., Prosser, H. M., Hewitt, C. R. A., Lamb, J. R., & Owen, M. J. (1992) · Hybridoma · doi:10.1089/hyb.1992.11.701 · Cited by 32

From bench to bedside: the history and progress of CAR T cell therapy

Mitra, A., Barua, A., Huang, L., Ganguly, S., Feng, Q., & He, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188049 · Cited by 466

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 396

Comprehensive analysis of spatial architecture in primary liver cancer

Wu, R., Guo, W., Qiu, X., Wang, S., Sui, C., Lian, Q., Wu, J., Shan, Y., Yang, Z., Yang, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3750 · Cited by 369

Immunogenicity of CAR T cells in cancer therapy

Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N., Hamieh, M., Hegde, M., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 303

Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

Crowther, M. D., Dolton, G., Legut, M., Caillaud, M. E., Lloyd, A., Attaf, M., Galloway, S. A. E., Rius, C., Farrell, C. P., Szomolay, B., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0578-8 · Cited by 267